TY  - JOUR
AU  - McEwan, Phil
AU  - Harrison, Cale
AU  - Binnie, Rhona
AU  - Lewis, Ruth D
AU  - Cohen-Solal, Alain
AU  - Lund, Lars H
AU  - Ohlsson, Marcus
AU  - von Haehling, Stephan
AU  - Comin-Colet, Josep
AU  - Pascual-Figal, Domingo A
AU  - Wächter, Sandra
AU  - Dorigotti, Fabio
AU  - de Arellano, Antonio Ramirez
AU  - Ponikowski, Piotr
AU  - Jankowska, Ewa A
PY  - 2023
DO  - 10.1002/ejhf.2788
UR  - http://hdl.handle.net/20.500.12105/16448
AB  - AIMSIron deficiency (ID) is comorbid in up to 50% patients with heart failure (HF) and exacerbates disease burden. Ferric carboxymaltose (FCM) reduced HF hospitalizations and improved quality of life when used to treat ID at discharge in patients...
LA  - eng
PB  - Wiley
KW  - Heart Failure
KW  - Iron Deficiencies
KW  - Anemia, Iron-Deficiency
KW  - Humans
KW  - Patient Discharge
KW  - Cost-Benefit Analysis
KW  - Stroke Volume
KW  - Quality of Life
KW  - Ventricular Function, Left
KW  - Ferric Compounds
KW  - Hospitalization
KW  - Maltose
TI  - Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation.
TY  - journal article
ER  -